PARAMUS, N.J.--(BUSINESS WIRE)-- <\/p>\n
Proteonomix, Inc. (OTC\/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an agreement with a leading provider of global clinical trial technologies and services, Numoda Corporation. <\/p>\n
Our engagement of Numoda is an important step in effectively and efficiently advancing the development of our proprietary therapeutics, said Proteonomix Chief Technology Officer Steven Byle. Numoda has a proven, innovative approach for assisting life sciences companies like Proteonomix to move through the clinical development process. We anticipate collaborating with the Numoda team on the Phase 1 clinical trial with our mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). <\/p>\n
On August 14, 2012, Proteonomix announced that the U.S. Food and Drug Administration had granted permission to the Company to initiate a Phase 1 clinical trial to evaluate UMK-121 in patients with ESLD. <\/p>\n
Numoda Corporation <\/p>\n
Philadelphia-based Numoda Corporation is a leading provider of clinical trial information and logistics services to promising life sciences companies. Numoda's services strengthen the business case for new therapies by ensuring efficient deployment of funds and immediate reporting for early assessment of progress to improve conditions for the acquisition of funding, licensing and partnering money for future success. The business offerings include business evaluation, budget projections and oversight, in conjunction with comprehensive management of clinical trials, patented information systems, logistics management and reporting tools with early visibility. Visit Numoda Corporation at http:\/\/www.numoda.com<\/a>. <\/p>\n About Proteonomix, Inc. <\/p>\n Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteodermis a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and plans to file an IND application for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http:\/\/www.proteonomix.com<\/a> and http:\/\/www.proteoderm.com<\/a>. <\/p>\n Certain statements contained herein are \"forward-looking statements\" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. <\/p>\n<\/p>\n Here is the original post: PARAMUS, N.J.--(BUSINESS WIRE)-- Proteonomix, Inc. (OTC\/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an agreement with a leading provider of global clinical trial technologies and services, Numoda Corporation. Our engagement of Numoda is an important step in effectively and efficiently advancing the development of our proprietary therapeutics, said Proteonomix Chief Technology Officer Steven Byle. Continue reading
\nProteonomix Engages Numoda Corporation for Clinical Trial Services<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"